Difference between revisions of "Vinflunine (Javlor)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=419548 NCI drug dictionary]: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=419548 NCI drug dictionary]: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity. | ||
| − | =History of FDA approval= | + | ==Diseases for which it is used== |
| + | *[[Bladder cancer]] | ||
| + | |||
| + | ==History of FDA approval== | ||
Not FDA approved; available in a number of other countries | Not FDA approved; available in a number of other countries | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Vesicant chemotherapy]] | [[Category:Vesicant chemotherapy]] | ||
| Line 12: | Line 14: | ||
[[Category:Microtubule inhibitors]] | [[Category:Microtubule inhibitors]] | ||
[[Category:Vinca alkaloids]] | [[Category:Vinca alkaloids]] | ||
| + | |||
| + | [[Category:Bladder cancer medications]] | ||
| + | |||
| + | [[Category:EMA approved drugs]] | ||
Revision as of 03:13, 4 March 2018
Mechanism of action
From the NCI drug dictionary: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.
Diseases for which it is used
History of FDA approval
Not FDA approved; available in a number of other countries